Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients

Journal of Viral Hepatitis

Volumn 19, Issue 12, 2012, Pages 836-842

  Charlebois, A ^a,b   Lee, L ^a,b   Cooper, E ^c   Mason, K ^c   Powis, J ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c South Riverdale Community Health Centre   (Canada)

^d TORONTO EAST GENERAL HOSPITAL   (Canada)

Author keywords

Group support; Hepatitis C virus; Housing; Interprofessional; Substance abuse; Treatment

Indexed keywords

ANTIVIRUS AGENT; COCAINE; ILLICIT DRUG; PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DEVELOPED COUNTRY; FEMALE; HEALTH CARE ACCESS; HEALTH PROGRAM; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HOUSING; HUMAN; IMMUNIZATION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; METHADONE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PSYCHOEDUCATION; RETROSPECTIVE STUDY; SUBSTANCE ABUSE; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS A VACCINES; HEPATITIS B VACCINES; HEPATITIS C; HUMANS; INTERFERONS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES; RIBAVIRIN; SELF-HELP GROUPS; SOCIAL MARGINALIZATION; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84868574534     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01648.x     Document Type: Article

References (29)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
2. Remis R,. A Study to Characterize the Epidemiology of Hepatitis C Infection in Canada, 2002. Final Report. Ottawa: Health Canada, 2004.
3. Shepard CW, Finelli L, Alter MJ,. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.
4. Patrick DM, Buxton JA, Bingham M, Mathias RG,. Public health and hepatitis C. Can J Public Health 2000; 91 (Suppl 1): S18-S23.
5. Nelson PK, Mathers BM, Cowie B, et al,. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-583.
6. Wong JB, McQuillan GM, McHutchison JG, Poynard T,. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562-1569.
7. Salomon J, Weinstein M, Hammitt J, Goldie S,. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-237.
8. Grebely J, Raffa JD, Lai C, et al,. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352-358.
9. Schaefer M, Heinz A, Backmund M,. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004; 99: 1167-1175.
10. Sylvestre DL, Zweben JE,. Integrating HCV services for drug users: a model to improve engagement and outcomes. Int J Drug Policy 2007; 18: 406-410.
11. John-Baptiste A, Varenbut M, Lingley M, et al,. Treatment of hepatitis C infection for current or former substance abusers in a community setting. J Viral Hepat 2009; 16: 557-567.
12. Grebely J, Knight E, Genoway KA, et al,. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22: 270-277.
13. Fischer B, Rehm J, Patra J, et al,. Crack across Canada: comparing crack users and crack non-users in a Canadian multi-city cohort of illicit opioid users. Addiction 2006; 101: 1760-1770.
14. Fischer B, Rudzinski K, Ivsins A, Gallupe O, Patra J, Krajden M,. Social, health and drug use characteristics of primary crack users in three mid-sized communities in British Columbia, Canada. Drugs: Educ Prev Policy 2010; 17: 333-353.
15. Shannon K, Rusch M, Morgan R, Oleson M, Kerr T, Tyndall MW,. HIV and HCV prevalence and gender-specific risk profiles of crack cocaine smokers and dual users of injection drugs. Subst Use Misuse 2008; 43: 521-534.
16. Treloar C, Holt M,. Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings. Aus Health Rev 2008; 32: 570-576.
17. Mehta SH, Genberg BL, Astemborski J, et al,. Limited uptake of hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-133.
18. Fitzpatrick-Lewis D, Ganann R, Krishnaratne S, Ciliska D, Kouyoumdjian F, Hwang SW,. Effectiveness of interventions to improve the health and housing status of homeless people: a rapid systematic review. BMC Public Health 2011; 11: 638.
19. Thomson H, Thomas S, Sellstrom E, Petticrew M,. The health impacts of housing improvement: a systematic review of intervention studies from 1887 to 2007. Am J Public Health 2009; 99 (Suppl 3): S681-S692.
20. Buchholz JR, Malte CA, Calsyn DA, et al,. Associations of housing status with substance abuse treatment and service use outcomes among veterans. Psychiatr Serv 2010; 61: 698-706.
21. Knowlton AR, Hua W, Latkin C,. Social support networks and medical service use among HIV-positive injection drug users: implications to intervention. AIDS Care 2005; 17: 479-492.
22. Lam JA, Rosenheck R,. Social support and service use among homeless persons with serious mental illness. Int J Soc Psychiatry 1999; 45: 13-28.
23. Reid KW, Vittinghoff E, Kushel MB,. Association between the level of housing instability, economic standing and health care access: a meta-regression. J Health Care Poor Underserved 2008; 19: 1212-1228.
24. Lee C,. Health, stress and coping among women caregivers: a review. J Health Psychol 1999; 4: 27-40.
25. Zickmund S, Ho EY, Masuda M, Ippolito L, LaBrecque DR,. "They treated me like a leper" Stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med 2003; 18: 835-844.
26. National Institutes of Health consensus development conference panel statement: management of hepatitis C. Hepatology 1997; 26: S2-S10.
27. Grebely J, Genoway K, Khara M, et al,. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18: 437-443.
28. Manns MP, McHutchison JG, Gordon SC, et al,. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
29. Hadziyannis SJ, Sette H, Morgan TR, et al,. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Inter Med 2004; 140: 346-355.